Relay Therapeutics stock fell 3.35 percent as officer filed to sell shares

Published on 10/07/2026 at 03:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A Rule 144 filing dated October 6 covers 93,153 shares valued at USD 1,806,236.67. Q2 revenue was USD 0.35 million versus a USD 0.96 million estimate.

RLAY, US75943R1023, Illustration mit AI erstellt.

Relay Therapeutics (ISIN US75943R1023) was last at USD 18.74 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 3.35 percent from the prior close. The immediate company catalyst was a Rule 144 filing covering a proposed sale of 93,153 shares by officer Thomas Catinazzo.

Officer filing adds a supply signal

According to Stock Titan on October 6, 2026, the filing listed an aggregate market value of USD 1,806,236.67 and 219,141,631 shares outstanding. The notice identifies Morgan Stanley Smith Barney as the broker and Nasdaq as the securities exchange.

The filing also shows earlier Rule 10b5-1 sales by Catinazzo, including 17,717 shares sold on September 8, 2026. For investors, the filing adds a company-specific supply factor to a session in which RLAY fell from a prior close of USD 19.39 to USD 18.74.

Second-quarter loss keeps cash burn visible

Relay's second-quarter results covered the period ended June 30, 2026. MarketBeat reported that revenue was USD 0.35 million against a USD 0.96 million estimate, while the quarterly loss was USD 0.41 per share versus a USD 0.39 per-share consensus loss.

The revenue gap matters because Relay remains a clinical-stage biotechnology company whose valuation depends on development progress rather than recurring commercial sales. A September 16, 2026 conference update said cash of USD 911 million at the end of the second quarter was intended to fund operations into 2029, according to Investing.com.

Analyst target stays above market quote

According to MarketBeat, 14 analysts carried a Moderate Buy consensus, comprising 10 Buy ratings, two Strong Buy ratings, one Hold and one Sell. The average 12-month target was USD 25.92, with a high of USD 31.00 and a low of USD 18.00.

Against the USD 18.74 Nasdaq quote on October 6, 2026, the average target places the price 27.7 percent below the consensus target. The range also shows a divided setup: the low target is below the market quote, while the average and high targets remain above it.

RLAY remains below its yearly high

Relay Therapeutics was last at USD 18.74 on Nasdaq on October 6, 2026, with a session range of USD 18.16 to USD 19.50 and volume of 3,879,838 shares. Its 52-week range was USD 5.47 to USD 21.27, leaving the stock 11.9 percent below the yearly high.